Genetic Analysis

The microbiome market is growing, but still in an early phase. Standardisation of diagnostics in this area is in great demand by pharma companies. Genetic Analysis has a prominent position for diagnostic tests. More approved drugs on the microbiome market are expected to drive growth as well as deals like Viome have done with CVS Pharma.

Mangold has chosen to adjust sales for 2023, taking into account previous inventory build up at customers which affected the valuation. Also coming years have been adjusted. It is still early in the sales cycle and sales depends on collaborations which gives uncertainty in our estimates. Mangold lowers the price target to SEK 3.40 (4.00) per share. This still leads to a large upside in the share of over 100 percent.